DGAP-News: EQS Group AG has excellent 2013 fiscal year EQS

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DGAP-News: EQS Group AG has excellent 2013 fiscal year

EQS Group AG / Key word(s): Final Results/Change of Personnel 11.04.2014 08:30 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer / publisher is solely responsible for the content of this announcement. --------------------------------------------------------------------------- EQS Group AG has excellent 2013 fiscal year Change in Management Board: Robert Wirth to leave EQS Group at year's end Munich - April 11, 2014 EQS Group AG (ISIN: DE0005494165) achieved excellent annual results for the 2013 fiscal year. Group revenue was EUR 15.829 million, representing an 11% increase over the previous year. According to IFRS, EBIT was down slightly by 2% to EUR 3.278 million. The Group's net profit was EUR 2.182 million, equalling EUR 1.83 earnings per share. For the period of October-December 2013, Group revenue was EUR 4.339 million. EBIT, according to IFRS, was EUR 1.331 million. The Group's net profit for the fourth quarter was EUR .960 million, equalling EUR 0.81 earnings per share. The Guidance issued at the start of 2013 regarding revenue was achieved, marking a new reporting high. The EBIT, however, fell slightly short of the prognosis due entirely to rent accruals for terminated office space in conjunction with the Group's planned move to a new company headquarter in Munich. Robust investment in the Group's expansion into Asia also had a negative effect on operating results. The EQS Group AG's board of directors and the supervisory board will propose a dividend payment of EUR 0.75 per share (as was paid in 2013, as well) at the general meeting on May 28, 2014. Operating cash flow in the 2013 fiscal year is EUR 2.476 million (EUR 2.025 million), with an equity ratio of 78% on December 31, 2013, and liquid assets equalling EUR 2.980 million. Achim Weick, EQS Group AG's CEO states: "The 2013 business year was very successful for us. We further solidified out dominant domestic market position and continued our international expansion. Despite sizeable investment in international growth, EQS Group operatively earned as much as it did the previous year." The Regulatory Information & News segment benefited from an 8% increase in distribution volume compared to the previous year. As expected, DGAP continued to be the first-choice supplier for statutory compliance services for publicly-listed companies in 2013. EQS Group's successful acquisition of euro adhoc's customer base in Germany and Switzerland showed positive effects, adding over 200 news customers and expanding its market position while stemming the negative trend of listed companies leaving the regulated market. The Products & Services segment also had an equally strong increase in revenue and results. Both the implementation of online annual reports as well as the financial reports submission service to the German Federal Gazette contributed to growth. The Group continued its geographic expansion. Our Russian subsidiary had a very successful 2013, resulting in its first profitable year. Our position as premium supplier offers excellent growth opportunities with Russian large caps. Furthermore, we have been able to continually strengthen our market position in Switzerland. The start-up EQS Asia Limited, domiciled in Hong Kong, began operations at the beginning of last year. Hong Kong's positive IPO climate, regulators' and investors' growing transparency demands, the city's geographical proximity to China and the nearby Asian-Pacific markets of Singapore and Taiwan together offer excellent growth possibilities for the EQS Group. Both our affiliate EQS Financial Markets & Media GmbH (100%) and our equity holding ARIVA.DE AG (25.44) contributed positively to the operating result. Change in Management Management Board member Robert Wirth requested the termination of his management contract in yesterday's Supervisory Board meeting, effective on December 31, 2014. The Board agreed to his request with deep regret. Rony Vogel, Chairman of the EQS Group AG Supervisory Board stated, "Robert Wirth helped to build the EQS Group from its very beginnings and his influence is deeply rooted within the company. He has worked tirelessly for 14 years with extraordinary knowledge and passion directed at the company's success. We understand his desire to dedicate more time to his private life and wish all the best." Robert Wirth intends to stand for membership in the supervisory board at the 2015 annual meeting while in the meantime maintaining his connection to the EQS Group as a consultant and shareholder. Christian Pfleger will succeed Robert Wirth in the Management Board, effective January 1, 2015. New Reporting Highs Expected in 2015 EQS Management intends to make the Group a worldwide leading international provider for online investor relations, a goal requiring further investment. Management therefore anticipates revenue increases of up to 10% to EUR 15.8-17.3 million with a shrinking EBIT of 15% to EUR 2.79-3.23 million. Management expects to set new sales record in the 2015 fiscal year, in revenues as well as EBIT. EQS Group's management will comment on the company results in today's conference call beginning at 11:00 a.m. (CET) to be transmitted live via internet at www.eqs.com. <pre> Key figures (IFRS) FY 2013 FY 2012 + / - Revenue (EUR million) 15.829 14.220 +11 % EBIT (EUR million) 3.278 3.351 -2 % Net profit (EUR million) 2.182 2.214 -1 % Earnings per share (EUR) 1.83 1.86 -1 % Earnings per share non-IFRS (EUR) 1.83 1.93 -5 % Cash flow from operations (EUR) 2.476 2.025 +22 % Liquid assets (EUR million) 2.980 2.748 +8 % Employees (period average) 105 105 0 % </pre> Further Notifications Q4 figures are unaudited. 2013 full-year figures are audited. The complete annual report can be found on www.eqs.com investor relations section, both as interactive and download version. You can also instantly receive free company notifications of EQS Group AG on your mobile device. We will inform you via text messages and offer news downloads to your smart phone. Please register under the investor relations section at www.eqs.com. About EQS Group Serving more than 7,000 international customers, EQS Group is the leading provider of online corporate communication services. For Investor Relations and Corporate Communications services, leading companies from Europe, Asia and North America use our web solutions, all from a single source. In addition to services aimed at ensuring companies comply with statutory requirements, the EQS service range includes dissemination of corporate news and press releases, development of financial portals, websites and apps, streaming of audio and video webcasts, and the creation of online financial reports. The market leader since its establishment in 1996, the Deutsche Gesellschaft für Ad-hoc-Publizität mbH or DGAP (a 100% EQS subsidiary) is a vital institution for publicly-listed companies' compliance with statutory requirements. Through its subsidiary Financial Markets & Media GmbH (100%) and a strategic holding in ARIVA.DE AG (25.44%), the EQS Group offers services for B2C investor relations, financial data and online advertising in the financial sector. The EQS Group employs 165 employees at its offices in Munich, Kiel, Hamburg, Zurich, Moscow, and Hong Kong. Contact: Robert Wirth EQS Group AG Seitzstra�e 23 D-80538 München Tel.: +49 89 21 02 98 - 34 Fax: +49 89 21 02 98 - 49 E-Mail: robert.wirth@eqs.com www.eqs.com 11.04.2014 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: EQS Group AG Seitzstra�e 23 80538 München Germany Phone: +49(0)89 210298-0 Fax: +49(0)89 210298-49 E-mail: info@eqs.com Internet: www.eqs.com ISIN: DE0005494165 WKN: 549416 Listed: Freiverkehr in Berlin, Düsseldorf, München (m:access), Stuttgart; Frankfurt in Open Market (Entry Standard) End of Announcement DGAP News-Service ---------------------------------------------------------------------------

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 308

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 337

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 9

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Antengene’s AnTenGager-D2 Advances in Cancer Treatment

Updated Category News Views 26

Antengene's AnTenGager-D2 Offers Fresh Hope Alright, let's dig into the latest buzz from the 2026 Society for Immunotherapy of Cancer conference about Antengene's AnTenGager-D2 platform. If you're not into biotech lingo, buckle up, because this is a ride into the future of cancer treatments—where science fiction might soon become science fact. A Novel Approach to Tumor...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 344

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 273

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 78

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 321

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading

Top 5 Most Recently Viewed Articles

BioSyent Inc. to Announce Q3 Financial Results This Month

Updated Category News Views 189

BioSyent Inc. to Announce Q3 Financial Results BioSyent Inc., a prominent player in the specialty pharmaceutical industry, is preparing to release its financial results for the third quarter and year-to-date period. This important announcement is scheduled for November 20, prior to the market opening. The report will cover the company's performance for the three and nine...

Continue Reading
Dr. Ryan Egeland Joins Solventum as Chief Medical Officer

Updated Category News Views 381

Solventum Welcomes Dr. Ryan Egeland as New CMO Solventum, a pioneering healthcare company, recently announced the appointment of Dr. Ryan Egeland, MD, as their Chief Medical Officer. In this significant role, Dr. Egeland will lead the Global Medical and Clinical Affairs team, amplifying clinician and patient voices within the organization. Fostering Collaboration and...

Continue Reading
MiningToken Revolutionizes Cryptocurrency With AI Power

Updated Category News Views 186

Introducing MiningToken's Innovative AI Cloud Mining Service Bitcoin and Ethereum are experiencing remarkable market dynamics as Bitcoin persists in a bullish trend and Ethereum has gained notable ground recently. As global interest in cryptocurrencies grows, effective mining strategies are crucial for profitability. Amidst rising operational costs, many individuals seek...

Continue Reading
Saluda Medical's EVA™ Sensing Technology Approved in Europe

Updated Category News Views 111

Saluda Medical Achieves Regulatory Milestone with EVA™ Technology Saluda Medical, Inc. (ASX:SLD) has made significant strides in the medical device industry by achieving CE certification for its next-generation EVA™ Sensing Technology. This advancement not only marks a major endorsement in Europe but also is recognized in Australia. Following FDA approval in December...

Continue Reading
ReadPartner Inc. Unveils Revolutionary AI Tool to Combat Misinformation

Updated Category News Views 291

ReadPartner Inc. Launches AI Feature to Tackle Misinformation ReadPartner Inc., a leader in AI-driven media intelligence solutions, is excited to announce the upcoming launch of a groundbreaking digital security feature named ProfileScreen. This innovative tool aims to address the pressing issue of misinformation that plagues social media platforms. The ProfileScreen...

Continue Reading